贝伐单抗与培美曲塞联合治疗中晚期非小细胞肺癌的临床疗效及不良反应

Clinical effect and adverse reaction of the combination of bevacizumab and pemetrexed in the treatment of advanced non-small cell lung cancer

目的探讨贝伐单抗与培美曲塞联合治疗中晚期非小细胞肺癌的临床疗效及不良反应。方法我院收治的非小细胞肺癌140例,经一线DP方案(多烯紫杉醇+顺铂)化疗4个周期病情得到有效控制后,随机选取70例进入贝伐单抗与培美曲塞联合治疗为实验组,另70例进入单用培美曲塞治疗为对照组。观察和比较两组化疗后的近期疗效及不良反应的发生情况。结果两组患者均没有CR,实验组PR、SD、RR及1年生存率优于对照组,但无统计学意义(P>0.05),实验组的DCR明显优于对照组,具有显著性差异(P<0.05)。两组患者在不良反应上的差异无统计学意义(P>0.05)。结论贝伐单抗联合培美曲塞在中晚期非小细胞肺癌的临床治疗上安全、有效,值得推广应用。

Objective To observe the clinical efficacy and adverse drug reaction of bevacizumab combined with pemetrexed in the treatment of non - small cell lung cancer. Methods 140 patients with non-small cell lung cancer were treated with the first -line DP （Docetaxel ＋ Cisplatin） chemotherapy for four cycles and got disease control, and then they were randomly divided into two groups. The experiement group was given bevacizumab and peme-trexed group （n = 70）, and the control group was given pemetrexed （ n = 70）. Their short-term therapeutic effect and adverse reaction were observed and compared. Results There was no CR case in the two groups, and the PR, SD, RR and 1 years survival rate of the experiment group were better than those of the control group, but there was no statistical significance （P 〉 0.05）. The DCR of the experiment group was significantly better than that of the control group with significant difference （P 〈 0. 05）. There was no significant difference in adverse reaction between the two groups （P 〉 0.05）. Conclusion The combination of bevacizumab and pemetrexed is safe and effective in the treatment of advanced non - small cell lung cancer, which is worthy of widely application.